REG - Chemring Group PLC - Trading update and contract wins

ChemringAnnouncement

12/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL0711Ma&default-theme=true

RNS Number : 0711M  Chemring Group PLC  12 September 2023

 

FOR IMMEDIATE RELEASE
 
             12 SEPTEMBER 2023

 

CHEMRING GROUP PLC

FY23 TRADING UPDATE AND CONTRACT WINS

 

Chemring Group PLC ("Chemring" or "the Group") today issues a scheduled
trading update for the period to 31 August 2023.

 

Current trading and outlook

Trading in the period has progressed as planned, with continued strong order
intake a notable highlight. This provides excellent visibility out to FY25.
Expected FY23 revenue is now fully covered by the order book and the outturn
for the year ending 31 October 2023 remains in line with the Board's and
current analyst expectations*. Achieving full year expectations is subject to
US Department of Defense ("US DoD") approval of certain countermeasure
deliveries, representing c.£25m of revenue, that have already been
manufactured and will be recognised once approval is received. The US DoD is
expected to grant approval subject to determination of the quality of raw
material provided by a third-party supplier that is outside of the control of
the Group. The Group is supporting all parties in resolving this matter.

 

The Group has received a number of significant orders during the period,
detailed below. As at 31 August 2023, order intake for the year to date was
£536m (31 August 2022: £365m) and the order book was £829m (31 August 2022:
£575m). Encouragingly, order cover for FY24 is building, with Countermeasures
& Energetics having 81% order cover of expected revenue and the shorter
cycle Sensors & Information sector having 54% cover.

 

Contract awards - Sensors & Information

 

Roke

 

In the Sensors & Information sector our specialist consulting and
technology business, Roke, has received a significant award valued at £40m to
deliver the next two years of Project ZODIAC for the UK Ministry of Defence
("UK MOD"). ZODIAC is the backbone of the British Army's Land ISTAR Programme,
and will deliver an integrated intelligence, surveillance, target acquisition,
and reconnaissance ("ISTAR") system, which will transform how the Army
undertakes data-led decision making in the Land environment to gain
operational advantage.

 

ZODIAC will provide an integrated and distributed system of applications and
underlying system architecture that will enable the Army to understand, decide
and act with greater precision and speed and digitally integrate with key
allied partners. Roke will act as the Prime Systems Integrator on this
advanced technology programme supported by a supply chain of some of the
world's leading technology companies. The Group expects to see deliveries
under this contract commence late in FY23 with the majority delivered in FY24
and early FY25.

 

Activity at Roke has remained extremely buoyant with order intake in the year
to date at £165m (31 August 2022: £124m) up 33%. As a result of this strong
order intake we expect Roke to achieve another record year in FY23, with
revenue exceeding £160m.

US Sensors

 

Having successfully completed a Low Rate Initial Production ("LRIP")
Production Readiness Review and a supporting Manufacturing Readiness Review in
May, our US Sensors business has been informed that the Milestone C
procurement decision in respect of the Joint Biological Tactical Detection
System ("JBTDS") program has been approved.

 

A LRIP contract, valued at $15m, was received in September 2023. Hardware
deliveries under this contract will be made over the next 10 to 14 months,
with a Full Rate Production contract expected to be awarded thereafter.

 

Contract awards - Countermeasures & Energetics

 

Energetics

 

In Energetics we continue to see increased levels of activity and demand in
the propellants and energetic materials markets as customers re‐evaluate
their operational usage and stockpile requirements associated with traditional
defence capabilities.

 

Our Norwegian business, Chemring Nobel, continues to work with a number of its
customers, including Northrop Grumman, Diehl Defence, Rheinmetall, and Nammo,
on establishing long-term supply agreements. Chemring Nobel now has a record
order book, providing significant visibility over the medium term.

 

In the US, our Chicago business has received multiple orders in the period
including two contracts totalling $23m to supply critical components to
Lockheed Martin, and a $11m order to supply key parts on the United Launch
Alliance ("ULA") Vulcan launch system including flight-critical initiators,
thrusters and cartridges. Our Chicago business now has a record order book
which is in excess of $100m.

 

Our three niche Energetics businesses, which design and manufacture high
precision engineered devices and specialist materials, continue to see strong
customer demand with order intake up 122% to £211m (31 August 2022: £95m).
This strong performance demonstrates the value that our customers place on
Chemring's niche products and reinforces our decision to invest in expanding
capacity at our Energetics sites.

 

Countermeasures

 

In Countermeasures we have continued to see sustained customer demand from
across our portfolio, maintaining our position as the world leader in the
design, development and manufacture of advanced expendable countermeasures. In
the year to date the Group's Countermeasures businesses received orders
totalling £141m (31 August 2022: £121m) and in the period since 30 April
2023 we received the following notable awards: $17m for the delivery of MJU-75
flares from our fully automated manufacturing facility in Tennessee in support
of the US DoD, and £24m for the delivery of a range of countermeasure
products in support of the UK MOD from our facility near Salisbury.

Full year results date

As previously announced, the results for the year ending 31 October 2023 will
be released on 12 December 2023.

 

Michael Ord, Chemring Group Chief Executive, commented:

 

"These significant order wins are illustrative of our leading technological
offering and the heightened customer demand that we are seeing in response to
increased global uncertainty. The growth in order intake across both sectors
demonstrates customer confidence in Chemring to develop and supply highly
effective solutions, builds our order cover for FY24, and positions the Group
well for the future."

 

-ENDS-

 

* The Group believes analyst forecasts for adjusted operating profit for the
year ended 31 October 2023 are in the range of £65.2m to £68.2m, with a
consensus of £66.9m.

 

For further information:

Rupert Pittman            Group Director of Corporate Affairs,
                   01794 463401

                                       Chemring Group
PLC

 

James McFarlane        MHP Communications
                            020 3128 8100

Ollie Hoare

 

 

Cautionary statement

This announcement contains forward-looking statements that are based on
current expectations or beliefs, as well as assumptions about future events.
These forward-looking statements can be identified by the fact that they do
not relate only to historical or current facts. Forward-looking statements
often use words such as anticipate, target, expect, estimate, intend, plan,
goal, believe, will, may, should, would, could, is confident, or other words
of similar meaning. Undue reliance should not be placed on any such statements
because they speak only as at the date of this document and, by their very
nature, they are subject to known and unknown risks and uncertainties and can
be affected by other factors that could cause actual results, and Chemring's
plans and objectives, to differ materially from those expressed or implied in
the forward-looking statements. There are a number of factors which could
cause actual results to differ materially from those expressed or implied in
forward-looking statements. Among the factors that could cause actual results
to differ materially from those described in the forward-looking statements
are: increased competition, the loss of or damage to one or more key customer
relationships, changes to customer ordering patterns, delays in obtaining
customer approvals for engineering or price level changes, the failure of one
or more key suppliers, the outcome of business or industry restructuring, the
outcome of any litigation, changes in economic conditions, currency
fluctuations, changes in interest and tax rates, changes in raw material or
energy market prices, changes in laws, regulations or regulatory policies,
developments in legal or public policy doctrines, technological developments,
the failure to retain key management, or the key timing and success of future
acquisition opportunities or major investment projects. Chemring undertakes no
obligation to revise or update any forward-looking statement contained within
this announcement, regardless of whether those statements are affected as a
result of new information, future events or otherwise, save as required by law
and regulations.

 

 

Notes to editors

 

·   Chemring is a FTSE-250 listed global business that specialises in the
manufacture of high technology products and the provision of services to the
aerospace, defence and security markets

·   Employing approximately 2,600 people worldwide, and with production
facilities in four countries, Chemring meets the needs of customers in more
than fifty countries

·   Chemring is organised under two strategic product segments: Sensors
& Information and Countermeasures & Energetics

·   Chemring has a diverse portfolio of products that deliver high
reliability solutions to protect people, platforms, missions and information
against constantly changing threats

·   Operating in niche markets and with strong investment in research and
development ("R&D"), Chemring has the agility to rapidly react to urgent
customer needs

 

www.chemring.com (http://www.chemring.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTLBMFTMTJBBFJ